Valneva, Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate

Valneva SE:Valneva And Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate.Have Completed Recruitment For Phase 2 Trial, Vla15-221, Of Lyme Disease Vaccine Candidate, Vla15.Trial Builds On Previous Positive Phase 2 Trials And Includes Both Adult And Pediatric Participants.Main Safety And Immunogenicity Readout Will Be Performed Approximately One Month After Completion Of Primary Vaccination Schedule.Objective Of Trial Is To Show Safety And Immunogenicity Down To 5 Years Of Age And To Evaluate Optimal Vaccination Schedule For Use In Phase 3.